NAT1 Human Gene Knockout Kit (CRISPR) KN221042 from OriGene Technologies

9620 Medical Center Drive # 200

Rockville, Maryland 20850

United States

Phone: 1-888-267-4436 (U.S. only) / 301-340-3188
301-340-9254

(1) Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosisBreast Cancer Research and TreatmentOctober 1, 2022Courtney E. McAleese, Neville J. Butcher, Rodney F. MinchinNAT1 gene was achieved through a human NAT1 gene knockout (KO) CRISPR/Cas9 kit (OriGene Technologies, KN221042). This kit contained two gRNA vectors, a donor vector with the green fluorescent protein gene and puromycin

(2) Loss of human arylamine N-acetyltransferase I regulates mitochondrial function by inhibition of the pyruvate dehydrogenase complexThe international journal of biochemistry & cell biologyMay 1, 2019Wang L, Minchin RF, Essebier PJ, Butcher NJ.the NAT1 gene using a human NAT1 gene knockout CRISPR/Cas9 kit (Origene Technologies, Rockville, MD; KN221042). NAT1 knockout was verified by PCR of genomic DNA, lack of NAT1 acetylation activity and Western blot

(3) Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stabilityPloS oneJanuary 1, 2018Wang L, Minchin RF, Butcher NJ.NAT1 The NAT1 gene was disrupted using a human NAT1 gene knockout CRISPR/Cas9 kit (OriGene Technologies, KN221042) according to the manufacturer’s instructions. The kit contained two gRNA vectors with predesigned NAT1

NAT1 Human Gene Knockout Kit (CRISPR)